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Bacillus anthracis, the causative agent of anthrax, secretes a tri-partite exotoxin that exerts
pleiotropic effects on the host. The puriﬁcation of the exotoxin components, protective
antigen, lethal factor, and edema factor allowed the rapid characterization of their physio-
logic effects on the host. As molecular biology matured, interest focused on the molecular
mechanisms and cellular alterations induced by intoxication. Only recently have researchers
begun to connect molecular and cellular knowledge back to the broader physiological
effects of the exotoxin. This review focuses on the progress that has been made bridging
molecular knowledge back to the exotoxin’s physiological effects on the host.
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INTRODUCTION
Bacillus anthracis is a Gram-positive sporulating bacterium that
is the causative agent of anthrax (Mock and Fouet, 2001). The
bacterium has two key virulence factors: a poly-γ-d-glutamic acid
capsule produced by gene products encoded on the pX02 plasmid
and a tri-partite exotoxin encoded on the pX01 plasmid (Mikesell
et al., 1983; Green et al., 1985). The exotoxin is composed of a
host-cell receptor binding protein named protective antigen (PA)
and two enzymatic proteins, lethal factor (LF) and edema factor
(EF; Stanley et al., 1960; Smith and Stanley, 1962). LF and EF have
no known activity on the host until they bind and then are sub-
sequently translocated to the target-cell cytosol by PA. Once LF
or EF is bound to PA, they are referred to as lethal toxin (LT) or
edema toxin (ET), respectively. For most hosts, bacteria must have
both the capsule and the exotoxin in order to be fully virulent.
Resultantly, exotoxin deﬁcient mutants have been used as vaccine
strains in animal models since the nineteenth century (Sterne and
Robinson, 1939; Tigertt, 1980). However, the elimination of exo-
toxin production in some B. anthracis strains, such as the Ames
strain, does not affect virulence in mice, while other strains, such
as UT500, have decreased virulence in cutaneous models of infec-
tion when exotoxin production is eliminated (Welkos et al., 1993;
Heninger et al., 2006; Chand et al., 2009).
Host-cell intoxication begins when PA binds to either tumor
endothelial marker 8 [TEM8, also known as anthrax toxin recep-
tor 1 (ANTXR1)] or capillary morphogenesis gene 2 [CMG2, also
known also anthrax toxin receptor 2 (ANTXR2); Bradley et al.,
2001; Scobie et al., 2003;Young andCollier, 2007]. PA can also bind
to β1 integrins, which potentiate the uptake of PA by macrophages
(Martchenko et al., 2010). The physiological role of TEM8 in
mammals has been implicated in binding the extracellular matrix,
directing endothelial migration and adhesion (Nanda et al., 2004;
Hotchkiss et al., 2005). Less is known about CMG2 but evidence
suggests a role in endothelial proliferation (Reeves et al., 2010). As
their names and functions suggest, TEM8 and CMG2 are highly
expressed in vasculature, but several studies have also noted their
presence in epithelial cells (particularly in respiratory epithelium,
intestines, and keratinocytes) as well as in immune cells (Bradley
et al., 2001; Scobie et al., 2003; Bonuccelli et al., 2005). Genetic
and biochemical studies have recently demonstrated that PA has
higher afﬁnity for CMG2 and plays a larger role in susceptibility
than TEM8 in mice (Liu et al., 2009). After PA binds to CMG2 or
TEM8, it is cleaved by furin to a 63 kDa isoform (PA63) which hep-
tamerizes (Milne et al., 1994; Gordon et al., 1995; Lacy et al., 2004).
Alternatively, PA can be cleaved by serum proteases independently
from cell binding (Ezzell and Abshire, 1992; Moayeri et al., 2007).
Reports differ, however, as towhether this phenomenon is a species
speciﬁc effect in mice or occurs in several animal models. While
the exact protease has not been discovered, it is sensitive to the
protease inhibitor leupeptin, heat sensitive, and dependent on cal-
cium. Once PA63 has heptamerized, it can bind both LF and EF
with up to three potential binding sites per heptamer (Mogridge
et al., 2002a,b). A more recent study also provides evidence that PA
can oligomerize into either a heptamer or an octomer. In compar-
ison to the heptamer, the octomer is more stable when unbound
to the host toxin receptor, perhaps enabling it to oligomerize and
pre-form the exotoxin complex in serum (Kintzer et al., 2009).
Protective antigen oligomerization is necessary for its associa-
tion with lipid rafts and clathrin-mediated endocytosis (Abrami
et al., 2003). After endocytosis, the exotoxin is sorted into intra-
luminal vesicles in the early endosome (Abrami et al., 2004). The
decreasing pH in the early endosome causes PA/TEM8 to undergo
a critical conformational change to insert into the membrane
and form a translocation pore (Milne et al., 1994). PA bound
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to CMG2, however, needs a lower pH than TEM8 (Rainey et al.,
2005). In either case, this leads to LF/EF translocation into the
intraluminal vesicle, which then reaches the cytosol when the
intraluminal vesicles fuse back into the late endosome membrane
or the autophagosome (Abrami et al., 2004; Ha et al., 2010).
Once in the cytosol, LF and EF can exert their effects on the
cell. LF is a zinc metalloprotease that cleaves the N-terminus from
several MEKs and prevents the activation of Erk1/2, p38, and JNK-
pathways (Duesbery et al., 1998; Pellizzari et al., 1999; Vitale et al.,
2000). EF is a calmodulin dependent adenylyl cyclase toxin that
raises cAMP levels to supra-physiological levels (Leppla, 1982). In
contrast to other cAMP elevating toxins, such as Bordetella per-
tussis adenylate cyclase toxin and cholera toxin, ET produces high
amounts of cAMP perinuclearly rather than at the cell membrane
(DalMolin et al., 2006). The increased cAMPcan then activate pro-
tein kinase A (PKA), exchange protein activated by cAMP (Epac),
and the guanine exchange factor Rap1 (Hong et al., 2007).
It should not escape notice that these exotoxins act on key sig-
naling pathways that are present in several types of cells across
many physiological systems. Similarly, TEM8 and CMG2 are
highly expressed in a myriad of tissues, allowing for the exotoxin
to act on several systems simultaneously. This has complicated
the understanding of the exotoxin’s effects on the host since these
pathways have several targets in a cell, which can lead to unique
effects for different cell types and organs. Since the 1950s, when
the exotoxins were ﬁrst puriﬁed and characterized as sufﬁcient
to cause lethality, tissue edema, or protection from subsequent
infection, research has been aimed to deﬁne the molecular mecha-
nisms of their actions. This review seeks to discuss how the cellular
and molecular mechanisms of cell intoxication caused by the B.
anthracis exotoxins lead to diverse, and at times contrary, physio-
logical and cellular changes in the host’s immune, cardiovascular,
endocrine, and nervous systems.
IMMUNOLOGICAL EFFECTS
The ability of B. anthracis to subvert the immune system is of
the utmost importance for the pathogen to complete its life-
cycle (Mock and Fouet, 2001). This fact has not escaped the
attention of researchers as there are a multitude of studies and
reviews that investigate how anthrax toxins affect the immune
system in order to establish and exploit a niche in the host (Bal-
dari et al., 2006; Tournier et al., 2009). This review will focus on
the effects of anthrax exotoxins on three main immunological
functions: chemotaxis,bacteriocidal activity,and exotoxin induced
pyroptosis/apoptosis of immune cells.
CHEMOTAXIS
Neutrophils are among the ﬁrst immune cells to respond to infec-
tions and are essential for clearance of many bacterial and fungal
pathogens. Therefore, it stands to reason that a swift inﬂux of
neutrophils is necessary to contain an infection by B. anthracis.
Indeed, some studies have indicated that neutrophils are necessary
for protection due their antibacterial activities (Liu et al., 2010).
Further, early production of pro-inﬂammatory cytokines, such
as IL-1β, can increase survival mediated by neutrophils (Moay-
eri et al., 2010). Both puriﬁed LT and ET inhibit neutrophil
chemotaxis by reducing F-actin formation in vitro (During et al.,
2005; Szarowicz et al., 2009). This leads to reductions in ran-
domvelocity,directed velocity toward formyl-Met-Leu-Phe (awell
characterized chemoattractant) and reduces polarization of the
leading and lagging edges of the cell. F-actin is further reduced
when the cells are treated with both LT and ET simultaneously,
demonstrating an additive role for both exotoxins (Szarowicz et al.,
2009). ET also reduces the expression of CD11b/CD18 (Mac-1 or
CR3), a β2 integrin that is important in neutrophil adhesion and
extravasation. This presumably would reduce diapedesis through
capillaries or epithelial layers to the site of infection; however, this
was not tested (Szarowicz et al., 2009). These studies are in contrast
to earlier work from Wade et al. (1985) which found ET increases
PMN chemotaxis and an in vivo observation that greater amounts
of neutrophils were found near injection sites of ET (Tessier et al.,
2007). The latter observation may reﬂect the indirect effects of
ET increasing production of inﬂammatory lipid mediators which
recruit neutrophils.
Macrophage chemotaxis is altered by both LT and ET simi-
larly to neutrophils. In vivo clodronate depletion of macrophages
sensitizes mice to infection during inhalational anthrax, demon-
strating a net protective function of macrophages (Cote et al.,
2004, 2006). In vitro treatment of macrophages and peripheral
blood lymphocyteswith either puriﬁedLTor ET reduces phospho-
rylation of Erk, presumably by independent mechanisms, which
lessens chemotaxis toward the chemoattractants SDF-1α andMIP-
1α (Rossi Paccani et al., 2007). Pharmacologically inhibiting Erk
phosphorylation with the MEK inhibitor PD98059 also reduces
chemotaxis, supporting the interpretation that the exotoxins are
targeting the MAPK pathway to reduce chemotaxis. Additionally,
the ET inhibitor adefovir is able to partially rescue chemotaxis.
Interestingly, the F-actin decrease found in During et al.’s (2005)
research was not observed in neutrophils treated with PD98059,
suggesting that chemotaxis was not inhibited in their experimen-
tal system. This could be due to MEK1 having unique effects in
macrophages and neutrophils or the F-actin reduction occurs via
another MAPK pathway. Similarly, puriﬁed ET increases the cell
migration of bone marrow derived macrophages (BMDM; Kim
et al., 2008). This migration is due to PKA stimulation activating
CREB. Several genes are then induced via CREB, including Sdc1,
which is necessary for the increased migration and actin redistri-
bution that occurs in ET-treated BMDMs. It is important to note
that there is no indication that the macrophages were moving in
the direction of a chemoattractant. This is a salient point in B.
anthracis exotoxin-mediated chemotaxis assays since an increase
in random migration is distinct from chemotaxis. As such, differ-
entiation between random migration versus chemotaxis should
be noted when interpreting these observations. Recombinant ET
administration, however, leads to an increase in total circulating
neutrophils and monocytes (Firoved et al., 2005). This may be the
result of an increase in chemotaxis out of the bone marrow, as
the bone marrow is depleted of pluripotent stem cells. Indeed, G-
CSF, a potent maturation factor for neutrophil progenitors, has a
cAMP response element in its promoter, which may explain both
the marked increase of neutrophils and G-CSF in the serum.
Lastly, dendritic cells (DCs), which represent a crucial link
between innate and adaptive immunity, have an increased abil-
ity to chemotax and invade matrigel when treated with puriﬁed
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ET (Maldonado-Arocho and Bradley, 2009). LT has been shown
to inhibit chemotaxis in PBMC’s; however, addition of puriﬁed
LT with ET also leads to an increase in chemotaxis compared to
untreated DCs (Rossi Paccani et al., 2007;Maldonado-Arocho and
Bradley, 2009). Additionally, recombinant ET is capable of activat-
ing glycogen synthase kinase (GSK) in DCs, which in turn is able
to fully activate CREB-mediated transcriptional changes shown
by Kim et al. to be involved with chemotaxis (Kim et al., 2008;
Larabee et al., 2011). It is unknown if GSK is involved with CREB
activation in either neutrophils or macrophages.
BACTERICIDAL ACTIVITY
In addition to their potent actions on chemotaxis, the B. anthracis
exotoxins are also able to reduce the bactericidal activity and
activation of the innate immune system. Intoxicating human
neutrophils with puriﬁed ET reduces phagocytosis, which is not
surprising given the potent effect ET has on neutrophil actin for-
mation (O’Brien et al., 1985). Additionally, puriﬁed ET reduces
the neutrophil’s oxidative burst. Recombinant LT’s role in the neu-
trophil oxidative burst has also been examinedwith twodiscordant
studies showing it either increases or decreases the oxidative burst
in human neutrophils (Crawford et al., 2006; Xu et al., 2008). Puri-
ﬁed LT also reduces the amount of pro-inﬂammatory cytokines
and chemokines in NB-4 cells, a neutrophil-like immortal cell line
(Barson et al., 2008). The effects of LT on human neutrophils may
be less pronounced due to the ability of human α-defensins to
neutralize LT, though it is unclear in what environments in vivo
α-defensin concentrations would be at sufﬁciently high levels to
mediate this inhibition (Kim et al., 2005).
While it is tempting to assume that an exotoxin’s effect on the
bactericidal activity of circulating phagocyteswill be similar to that
of a resident phagocyte, research has indicated there are important
differences. Resident phagocytes have previously been implicated
as acting as a Trojan horse for B. anthracis spores (Ross, 1957;
Dixon et al., 2000; Guidi-Rontani, 2002). That is, the spore is
phagocytosed by alveolar macrophages (AMs) or lung DCs, which
then migrate with the spore to the draining mediastinal lymph
node. During the migration, the spore germinates, replicates, and
escapes from the phagocyte into the lymph node from which it can
later spread to the blood. However, human AMs are more resis-
tant to MEK1 cleavage and LT-mediated cytokine inhibition than
peritoneal macrophages or the murine RAW264.7 macrophage-
like cell line (Wu et al., 2009). Further, PA does not bind AMs
well, despite similar transcription levels of CMG2 compared to
RAW264.7 cells. This might be due to single nucleotide polymor-
phisms (SNPs) in human macrophages. Genetic susceptibility to
exotoxin uptake was explored in an in vitro system where lym-
phoblastoid cells derived from 234 cohorts in the HapMap Project
(Martchenko et al., 2012). Cells were treated with PA and FP59,
a heterologous cargo protein for the PA oligomer that rapidly
kills lymphocytes in a manner independent from either LT or
ET, to assess their relative capacity for intoxication. Susceptibil-
ity to intoxication varies 30,000-fold, with three cell lines showing
a much higher level of resistance. Excluding these three outliers,
there is still a 250-fold range of resistance between individuals.
This suggests that human cells have varying ability for exotoxin
uptake. Further, a SNP that causes a P357A substitution in the
human CMG2 region involved with PA internalization reduces the
amount of PA uptake in transgenic RAW264.7 cells (Martchenko
et al., 2012). It is likely, however, that AMs are uniquely resistant to
LT-mediated death as the AMs inWu’s studies were likely collected
from several individuals. AMs from Cynomolgus macaques, how-
ever, do have reductions in cytokine production when intoxicated
with puriﬁed LT in vitro, likely due to the effects of MEK1 cleav-
age (Ribot et al., 2006). Therefore, in addition to differential
responses between human and mouse AMs, important species
difference in the intoxication of immune cells exist even in very
closely related non-human primates and humans. Despite the dif-
ference in cytokine production, both studies demonstrate stark
differences in the viability of AMs when compared to circulating
monocytes/macrophages andmacrophage-like cell lines (Pellizzari
et al., 1999; Popov et al., 2002; Wu et al., 2009). ET intoxication
of Guinea pig AMs with puriﬁed ET reduces their secretion of
Type-IIA phospholipase A2 (Raymond et al., 2007). This enzyme
not only activates innate immunity through the production of
arachidonic acid, but also is able to exert a direct bactericidal
activity. Accordingly, infection of Guinea pigs with an EF deﬁ-
cientB. anthracis strain does not reduce phospholipaseA2 activity.
It would be interesting to determine if ET can induce increased
cAMP and a decrease in Type-IIA phospholipase A2 in human
AMs given the report of poor PA binding to these cells.
There is also conﬂicting data as to whether circulating
monocytes/macrophages produce more or less pro-inﬂammatory
cytokines after exposure to puriﬁed LT. This is in part due to the
ability of macrophages in some rodent inbred strains to undergo
pyroptosis in response to LT intoxication (described in further
detail below; Friedlander et al., 1993; Hanna et al., 1993; Bergs-
baken et al., 2009). Addition of LT to monocytes prevents dif-
ferentiation into macrophages in vitro (Kassam et al., 2005) and
reduces the amount of TNFα and IL-1β produced by macrophages
in response to stimuli (Erwin et al., 2001). Further, both low doses
of recombinant LT and ET reduce the ability of macrophages
to phagocytose (Yeager et al., 2009; Kau et al., 2010). In agree-
ment with the protective roles of macrophages, spore-infected
mice supplemented with mutant macrophages that are resistant
to LT-mediated lysis (see more details below) had higher survival
rates than those supplemented with exotoxin-sensitive RAW264.7
cells. The mice with the mutant LT-resistant macrophages had
lower bacterial burdens 18 h post-infection than controls. There
is no difference in mouse survival between mutant LT-resistant
and parental macrophages when infected with vegetative bacteria,
potentially indicating an exotoxin-independent mechanism, such
as capsule for phagocyte evasion (Cote et al., 2008).
NK cells were ﬁrst identiﬁed as being involved in anthrax
immunity when it was noted that formaldehyde inactivated spores
(FIS) induce a large increase in IFN-γ and IL-12p40 in murine
splenocytes (Glomski et al., 2007). Incubating splenocytes with
anti-IL-12 antibodies abrogates the increase in IFN-γ produc-
tion, strongly suggesting that IL-12 production is necessary for the
increase in IFN-γ. Further, this increase is dependent on MyD88
signaling as splenocytes from MyD88−/− mice do not respond
with an increase of either of these cytokines.Within the spleen, the
CD11b+ population (macrophages and some DCs) are responsi-
ble for the IL-12 production,whereas the CD49b+ population (the
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majority of NK and NKT cells) produces the IFN-γ. Addition of
puriﬁed LT to splenocytes disrupts a paracrine feedback loop that
is known to increase the bacteriocidal activity of macrophages and
monocytes as well as increase inﬂammation in the host.
A recent study further delineated the mechanism of the
macrophage-NK interactions and its role in vivo (Klezovich-
Bénard et al., 2012). BMDM induce IFN-γ production in NK
cells after exposure to B. anthracis spores through direct contact
of macrophage RAE-1 ligand to their activating NKG2D recep-
tor. Neutralization of either RAE-1 or NKG2D by monoclonal
antibodies led to a decrease in IFN-γ and this IFN-γ decrease is
additive if both antibodies are included. Furthermore, addition of
spores to BMDM led to an increase in RAE-1 expression. RAE-1
is expressed due to TLR signaling through MyD88, in agreement
with the previous publication noting that MyD88 is necessary for
this macrophage-NK paracrine function (Hamerman et al., 2004).
Furthermore, IL-18 and IL-15 are necessary for the IL-12 medi-
ated IFN-γ production. Puriﬁed LT decreases IFN-γ release from
NK cells by preventing IL-12/IL-18 production via reduced phos-
phorylation of p38, JNK, and ERK. LT treatment does not lead
to increases in cell death as determined by cell permeability, but
it does reduce metabolism when analyzed using mitochondrial
reductase assay. While puriﬁed LT acts on NK cytokine secretion,
puriﬁed ET leads to only a slight reduction in IFN-γ production
at high concentrations when splenocytes are exposed to FIS. How-
ever, puriﬁed ET reduces IL-12 released by macrophages/DCs to
basal levels, thereby reducing IFN-γ production indirectly. ET also
reduces IL-18 production when exposed to FIS, as addition of IL-
18 can restore IFN-γ levels in splenocytes treated with puriﬁed ET.
Further, both puriﬁed LT and ET reduce the ability of NK cells to
lyseMHCclass I-deﬁcient cells in vitro and in vivo. Lastly, infection
of mice with either ET only or LT only-expressing strains leads to
a decrease in migration of NK and F4/80+ cells to draining lymph
nodes.
Gonzales et al. (2012) similarly found a decrease in IFN-γ, but
no changes in apoptosis when incubating human NKs and mono-
cytes with puriﬁed LT. Conversely to mouse NK cells, human NK
cells treated with puriﬁed LT or ET were still capable of lysing
MHC class I-deﬁcient K562 cells. Both studies demonstrated the
NKs delayed dissemination of B. anthracis in both cutaneous and
inhalational models of infection; however, Gonzales et al. noted
that NK deﬁciency did not alter the pathology or the survival
kinetics. In agreement with this, NK cells greatly enhance the
bactericidal activity of infected monocytes and surprisingly can
cause a ∼2 log10 decrease in extracellular vegetative bacilli. While
NK-macrophage/monocyte enhancement was well described in
Klezovich-Bénard’s work, the mechanism by which NK cells are
able to kill bacilli is unknown. The authors suggest that natural
cytotoxicity receptors, which have been shown to have an effect
on other bacteria, may bind a yet to be discovered ligand on B.
anthracis. It is unknown if the activity of these cytotoxic receptors
are altered by exotoxin.
Lethal toxin can also induce anergy in Type I CD1d-restricted
natural killer T (NKT) cells (Joshi et al., 2009). These cells are a
class restricted T cell that express a semi-invariant T cell receptor,
CD1d lipid speciﬁc antigen presentation molecule, and the NK1.1
molecular marker. These cells occupy a unique niche in the host
between the innate and adaptive immune systems. NKT cells also
express CMG2 and TEM8 at greater quantities and bind PA to a
greater extent than other splenocytes. Intoxication with puriﬁed
LT led to a large decrease in NKG2D expression by NKTs, yet this is
not seen in NK cells. Further, addition of puriﬁed LT to NKT cells
led to decreases in CD69 as well as increases in Ly49 inhibitory
receptors. Similarly to NK cells, there was no decrease in cell via-
bility. NKT cells are also noted for their ability to be stimulated
with the glycolipid alpha-galactosylceramide (α-GC) to produce
IFN-γ and IL-4. Ex vivo stimulation of splenocytes with α-GC
from a mouse treated with puriﬁed LT led to a decrease in both IL-
4 and IFN-γ. Co-culture assays using splenocytes harvested from
an NKT deﬁcient mouse treated with puriﬁed LT and LT treated
NKTs expanded ex vivo demonstrate that the IFN-γ production
comes from the NKT cell and that splenocytes and NKT cells are
synergistically involved in IFN-γ production.
Dendritic cells, T, and B cells are also affected by exotoxins,
though as mentioned in a previous review, it is not certain what
role this plays given that anthrax is an acute disease and there is
evidence that survivors have long lasting immunity (Ingram et al.,
2010; Moayeri and Leppla, 2011). It is possible that DCs, T, and B
cells increase the activation and bacteriocidal activity of the innate
immune system indirectly through cytokine and chemokine pro-
duction. In support of this, in vitro addition of puriﬁed exotoxins
reduce the amount of pro-inﬂammatory cytokines produced by
human and murine DCs (Agrawal et al., 2003; Brittingham et al.,
2005; Tournier et al., 2005; Cleret et al., 2006). Splenic DCs that
are intoxicated with puriﬁed LT are deﬁcient in stimulating T cell
proliferation (Agrawal et al., 2003). Further, there is evidence that
puriﬁed LT can induce cell death in immature, but not mature,
DCs (Alileche et al., 2005; Reig et al., 2008). This is complicated
by the fact that recombinant ET can induce maturation of imma-
ture DCs, a feature that has been demonstrated with other cAMP
increasing agents (Galgani et al., 2004; Maldonado-Arocho and
Bradley, 2009). It is worth noting that DCs are a very diverse
class of cells that originate from separate precursors and have dif-
ferent roles (Banchereau et al., 2000). Thus, anthrax exotoxins
may have unique effects on different subtypes of DCs. In support
of this, bone marrow derived DCs infected with a B. anthracis
strain expressing both exotoxins do not have defects in matura-
tion (Tournier et al., 2005; Cleret et al., 2006). Yet, infecting lung
DCs (LDCs) with spores from a strain that produced LT only or
both LT and ET leads to a decrease in LDC activation (Cleret et al.,
2006). Therefore, it is possible that in addition to AMs, resident
lung DC’s have unique responses to LT and ET and LDCs may be
speciﬁcally targeted by LT in inhalational infections.
Beyond the previously mentioned decrease in DC-mediated
stimulation of T and B cells, both LT and ET are capable of directly
suppressing immune cell proliferation, similar to the effect of ET
on the murine J774.A1 macrophage-like cell line (Comer et al.,
2005; Paccani et al., 2005; Fang et al., 2006; Gray and Hewlett,
2010). Puriﬁed exotoxins are also sufﬁcient to reduce cytokine
and IgM production (Fang et al., 2006). As discussed above, T and
B cells have powerful roles in regulating the innate immune system
and may have an important role in directing the innate immune
response. This is underscored bypuriﬁedET inducing the develop-
ment of T helper cells to a TH2 and TH17 phenotype, depending
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on the amount of ET added (Rossi Paccani et al., 2009; Paccani
et al., 2011). The latter development is surprising given that TH17
invokes a potent antimicrobial effect. At present, there is little data
on the effect of LT on T helper polarization, so it is unknown
if these effects would be mitigated during co-intoxication. It is
tempting to speculate that the reduction of IFN-γ from NK cells
plays a role in this polarization toward TH2/TH17.
PYROPTOSIS AND APOPTOSIS OF IMMUNE CELLS
Finally, host immune cells are particularly susceptible to multiple
forms of cell death when intoxicated by B. anthracis’ exotoxins.
Macrophages are vulnerable to LT-mediated death (Friedlander,
1986; Friedlander et al., 1993),but a large body of work has focused
on the ability of some mouse strain macrophages to generate a
potently pro-inﬂammatory and rapid cell death called pyroptosis
(further discussed below; Hanna et al., 1993; Bergsbaken et al.,
2009). For the purposes of this review, macrophages that undergo
pyroptosis are referred to as LT-sensitive and macrophages that
experience a slow apoptotic death are referred to as LT-resistant.
Interestingly, mice that have LT-sensitive macrophages are gener-
ally resistant to anthrax spore infections and those strains that suc-
cumb to anthrax tend to have LT-resistant macrophages (Welkos
et al., 1986). This sensitivity is due to several genetic factors,
but the majority of research has focused the allelic variants of
Nalp1b/Nlrp1b (Boyden and Dietrich, 2006). Yet, there are excep-
tions to this correlation between Nlrp1b-sensitive mice and rapid
death due to puriﬁed LT injection; e.g., C3H mice macrophages
rapidly lyse when exposed to high concentrations of puriﬁed LT,
but the mice have greater survival after LT injection than the LT-
sensitive Balb/c strain (Moayeri et al., 2004). These exceptions
suggest that there may be several loci that confer lethality to the
host, but the Nalp1b-sensitive allele is sufﬁcient for macrophage
pyroptosis (McAllister et al., 2003; Moayeri et al., 2004). Indeed,
there is some data that pyroptosis by itself may have host pro-
tective effects. Transgenic mice that have an LT-sensitive Nalp1b
allele in an otherwise resistant background have a greater resis-
tance to spore challenge than the parental LT-resistant Nalp1b
mouse strain and have greater recruitment of neutrophils into
the peritoneal cavity during a peritoneal infection (Terra et al.,
2010). Therefore, mice with the LT-sensitive Nalp1b allele have
a greater early pro-inﬂammatory response due to LT intoxica-
tion, suggesting that an increased pro-inﬂammatory response is
protective against B. anthracis infection. Similar ﬁndings sup-
port that this Nalp1b-sensitive protection is linked to neutrophil
recruitment in a subcutaneous infection model (Moayeri et al.,
2010). Finally, pyroptosis in response to puriﬁed LT exposure has
only been reported in macrophages and DCs of mouse and rat
strains (Roberts et al., 1998; Alileche et al., 2005); therefore, the
role of Nlrp1b in human pathogenesis is unclear. At lower doses
(or higher doses for non-sensitive strains/organisms) puriﬁed LT
induces apoptosis in macrophages and DCs (Park et al., 2002;
Popov et al., 2002; Alileche et al., 2005; Reig et al., 2008). To date,
only Voth et al. (2005) have reported ET to be directly cytotoxic
to both zebraﬁsh embryos and RAW264.7 macrophage-like cells.
However, ET inhibits cell cycle progression in the J774.1A and
RAW264.7 macrophage-like cell line (Larabee et al., 2008; Gray
and Hewlett, 2010). It is unknown if this delay leads to apoptosis
or whether it is unique to macrophages.
CARDIOVASCULAR EFFECTS
HYPOXIA VS. SEPTIC SHOCK
Systemic anthrax has long been known to affect the cardiovas-
cular system and lead to cyanosis as well as large decreases in
pulse and blood pressure in the ﬁnal stages of infection in many
animal models and human case studies (Cui et al., 2004, 2007;
Klempner et al., 2010; Sweeney et al., 2010). What has become
clearer is that the exotoxins not only target the vasculature, but also
the cardiac tissue. Early anthrax research suggested that the exo-
toxin induced immunopathology due to sepsis and this led to the
vascular damage and shock at terminal stages. In the past 10 years,
however, there has been growing credence to the hypothesis that
the shock-like phenotype of anthrax is due to cardiovascular dam-
age directly from exotoxins rather than immunopathology from
intoxicated host-cells. Injection of puriﬁed LT inmice leads to host
tissue damage more consistent with hypoxia, rather than endo-
toxin/macrophage induced septic shock (Moayeri et al., 2003).
Post-mortem histology from LT-injected BALB/cJ mice demon-
strates a lack of indicators of cytokine-induced shock, e.g., ﬁbrin
clots and capillary thrombosis in the liver, kidney dysfunction,
or extended increased production of pro-inﬂammatory cytokines.
Rather, hypoxic response proteins rapidly increase after LT injec-
tion. This contrasted earlier work from Hanna and Collier which
concluded that the rapid death from LT injection was due to
increased cytokine production from macrophages (Hanna et al.,
1993). Further, depletion of macrophages and antibody medi-
ated neutralization of IL-1 protects mice from LT-mediated death.
Adoptive transfer of RAW264.7 cells, which are sensitive to LT-
mediated pyroptosis and secrete IL-1β, into macrophage-depleted
mice re-establishes the rapid death phenotype (Hanna et al., 1993).
Subsequent studies, however, have shown evidence that LT pre-
dominantly suppresses pro-inﬂammatory cytokine production
even when LPS is used as the stimulus (Pellizzari et al., 1999; Cui
et al., 2004, 2006). Similarly, slow infusion of LT into rats reduces
cytokines in serum when compared to rats that received LPS only.
Delivery of puriﬁed ET can also exert pro-inﬂammatory effects
with some cytokines, but since ET does not induce pyroptosis,
it has never been implicated as causing pro-inﬂammatory septic
shock (Firoved et al., 2005).
Infusions or boluses of puriﬁed exotoxin do not completely
replicate the pathology of anthrax and toxemia should not be
thought of as recapitulating the bacterial infection. In contrast
to the Moayeri hypoxia study, necropsies from B. anthracis infec-
tions show ﬁbrin deposits and vasculitis in several animal models
(Twenhafel, 2010).What is striking is that the bacilli can reach such
high numbers in hosts before there are any overt signs of morbid-
ity. Since the majority of data support an anti-inﬂammatory role
of LT and ET, it is possible that anthrax exotoxins are temporar-
ily reducing immunopathology by reducing the amount of pro-
inﬂammatory cytokines produced by the host. Similar to the effect
of anthrax exotoxin reducing the amount of pro-inﬂammatory
cytokines in immune cells, several reports have shown that LT
reduces pro-inﬂammatory cytokines in endothelial cells. IL-8 tran-
scripts are destabilized by LT via dephosphorylation of the RNA
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regulation protein tristetraprolin (Batty et al., 2006; Chow et al.,
2010). In addition, puriﬁed LT suppresses tissue factor production
and NF-κB upregulation when endothelial cells are stimulated by
LPS (Rao et al., 2004). Perhaps the reduction of the inﬂammatory
response is critical early in infection to protect the bacteria from
innate defenses as they initially colonize and then progress toward
dissemination to the blood stream. Although few studies have
looked at the effect of B. anthracis peptidoglycan on host-cells, the
pro-inﬂammatory responses induced by peptidoglycan require the
p38 MAP kinase pathway that are in turn inhibited by puriﬁed LT
(Langer et al., 2008; Iyer et al., 2010). Additionally, sub-lethal doses
of LT can result in slight reductions of pro-inﬂammatory cytokines
in rats injected with E. coli or its puriﬁed LPS (Cui et al., 2006).
In contrast to the anti-inﬂammatory role of LT to the endothe-
lium, LT has an additive effect with TNF-α to up regulate VCAM
expression in human endothelial cells (Steele et al., 2005). Further
studies are necessary tounderstand themechanismand limitations
of exotoxin to prevent immunopathology via peptidoglycan.
EFFECTS ON VASCULATURE
Although the exotoxins decrease host immunopathology at some
stages of infection, there is evidence that LT and ET induce dam-
age to the vasculature and increase permeability. Increased leakage
or hemorrhage of the vasculature is commonly associated with
anthrax in non-human primate models (Twenhafel, 2010). Treat-
ment of primary human endothelial monolayers with puriﬁed LT,
but not its individual components, increases the permeability in a
concentration and time dependent manner (Warfel et al., 2005).
Microscopic analysis further shows cell elongation, interepithelial
gaps, and a reduction of surface vascular endothelial cadherins.
While there is a small decrease in cell metabolism and low levels
of apoptosis at 48 and 72 h post-addition, this is not sufﬁcient
to cause the increased permeability seen with LT treatment. In
agreement with this, treatment with a cocktail of MAP kinase
inhibitors recapitulates the permeability defect. Another study
found that addition of puriﬁed LT to human umbilical endothelial
cells (HUVEC) induced signiﬁcant amounts of apoptosis (Kirby,
2004).
A unique method of investigating the effect of injected puriﬁed
LT on vasculature in vivo utilized transparent zebraﬁsh embryos
(Bolcome et al., 2008). This model allows visualization of the pro-
gressive endothelial permeability and cardiovascular dysfunction
in real time. Enlargement of the cardiac chambers ﬁrst occurs,
followed by a rapid increase in vascular permeability and interseg-
mented vessel collapse. Later a narrowing of the outﬂow tract from
the heart and pericardial edema results in a cessation of blood ﬂow.
Vascular collapse occurs with no signs of decreased cell prolifer-
ation and with little cell death. Endothelial growth, proliferation,
and permeability are in part regulated by vascular endothelial
growth factor (VEGF) and VEGF receptors (VEGFR). VEGFR
inhibitors can partially abrogate the effects of LT on vascular per-
meability (Bolcome et al., 2008). Whether LT’s effect on VEGF
pathways is independent from MAPK pathways is unknown. Vas-
cular leakage in mouse models show similar results using a Miles
assay, which uses intravenously delivered Evan’s blue dye to quan-
tify macromolecular vascular leakage. Subcutaneous injection of
puriﬁed LT leads to a rapid (15–25min) and dose dependent
response in mice (Gozes et al., 2006). This rapid response to LT
suggests that vascular leakage is due to a transcription/translation
independent event. The fact that ketotifen, a histamine inhibitor,
can greatly reduce the amount of leakage lends credence to this
idea, though it is uncertain via which mechanism or on which cell
ketotifen is functioning. The ability and degree of leakage varies
between inbred mice strains and has no correlation to strain sus-
ceptibility to LT-mediated death (Gozes et al., 2006). Therefore,
LT-mediated death may be due both to vascular leakage and the
host’s response to the leakage. Moreover it is unknown how MEK
cleavage by LT could lead to such a rapid response.
Lethal toxin and ET can also affect endosomal recycling path-
ways, which can result in vasculature leakage. LF and EF reduces
both Notch receptor and surface protein levels of the Notch lig-
and Delta when endogenously expressed by a GAL4 promoter
in Drosophila melanogaster (Guichard et al., 2010). Notch and
Delta are members of the Notch signaling pathway, which has
crucial roles in embryogenesis and cell to cell communication.
EF also down regulates the production of Serrate, another Notch
ligand. Both of these exotoxins target the recycling of the Delta
ligand that is necessary for proper DE-cadherin expression at cell
junctions. The decreased cadherin expression leads to reduced
cell to cell contact and therefore increases permeability. EF inter-
feres with the Rab11 and Sec15 complex, whereas LF targets only
Sec15 vesicles. Sec15/Rab11 are also inhibited by ET and LT in
human brain microendothelial cell lines (hBMEC), leading to a
decrease in membrane cadherin expression. Transwell assays also
demonstrated an increase in hBMEC permeability.
There is conﬂicting data on ET’s role in inducing vascular
leakage. Addition of puriﬁed ET induces transendothelial cell
macroapertures (TEM) in HUVEC monolayers and their forma-
tion correlates with the increase in permeability. These TEMs are
resealed by the host via Missing in Metastasis protein through
actin polymerization, suggesting a complicated balance in the
maintenance of endothelial integrity (Maddugoda et al., 2011).
Conversely, Tessier et al. (2007) found that administration of
puriﬁed ET to HUVECs increased transepithelial electrical resis-
tance (TEER) and suggested that ET induced edema indirectly
by increasing inﬂammatory lipid mediators in vivo. Furthermore,
pharmacological inhibition of prostanoids, histamines, and neu-
rokinins (which were postulated to induce histamine production)
reduced edema formation via vascular leakage. The source of
neurokinins is unknown, but it could come from immune cells,
ﬁbroblasts, endothelial, or quite intriguingly, sensory neurons.
Finally, host control of endothelial permeability has a very
important role in regards to the bloodbrain barrier (BBB),which is
composedof a single layer of brainmicroendothelial cells (BMEC).
Anthrax is not commonly thought of as a disease that results in
meningitis; yet, data has shown that ∼50% of patients with sys-
temic anthrax developed meningitis, far greater than many other
bacterial causes (Abramova et al., 1993). B. anthracis is able to
adhere to and be internalized by the BMEC and this invasion is
potentiated by the presence of the exotoxin encoding genes. Addi-
tionally, infection in a meningitis model leads to inﬂamed and
thickened meninges in 63% of infected mice (van Sorge et al.,
2008). Further, adherence and invasion is aided by both bacterial
exotoxins and the adhesin BslA. ZO-1+ tight junctions in BMEC
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monolayers exposed to non-encapsulated Sterne strains are dis-
rupted to a greater extent than either the ΔbslA mutant or the
ΔET/LT mutant (Ebrahimi et al., 2009). Infections with exotoxin
deﬁcient bacterial strains demonstrate that ET is necessary to dis-
rupt the barrier function in BMECmonolayers, but LT is necessary
for invasion. In vivo meningitis models of CD-1 mice show that
LT is necessary for bacteria to reach the brain; however, it could
be that the LT deﬁcient strain is attenuated and cannot establish a
productive infection in these mice.
EFFECTS ON CARDIAC TISSUE
There is also evidence that anthrax exotoxins cause early cellu-
lar cardiac damage that leads to later physiologic dysfunctions.
Nitric oxide (NO) has crucial and pleiotropic roles in vasculature
control and its production is targeted by LT.Of the threemajor iso-
forms of nitric oxide synthases, only neuronal nitric oxide synthase
(nNOS) demonstrates a decrease in survival between nNOS−/−
mice and their wild type (WT) control when injectedwith puriﬁed
LT (Moayeri et al., 2009). Further, cardiac tissue from nNOS−/−
mice has vacuoles between ﬁbers of the tissue and suggestions of
mitochondrial damage. Ultrastructure analysis indicate damage in
both the nNOS−/− and, at later time points, the WT mice. Addi-
tionally, cardiac tissue from both nNOS−/− and their WT controls
have grossly elevated levels of cardiac injury markers c-Troponin-
I, myoglobin, and heart-type fatty acid binding protein. One of
the protective roles of nNOS is to scavenge reactive oxygen species
(ROS) produced in cardiac tissues when stressed. Presence of ROS
reduces the contractility of myocytes via reduction of response to
Ca2+ stimulus (Akki et al., 2009). nNOS is thought to suppress
superoxide generation by negatively regulating xanthine oxidore-
ductase (XOR), but treatment with allopurinol, a XOR inhibitor,
exacerbates death versus controls (Khan et al., 2004;Moayeri et al.,
2009). A later paper, however, reported that in vitro myocytes
had an increase in superoxide production when treated with LT.
Moreover, suppressing NADPH oxidase activity with the inhibitor
apocynin largely suppresses the decreased contractility caused by
LT (Kandadi et al., 2010). Therefore it is tempting to speculate that
nNOS may have a role in suppressing LT-induced NADPH oxidase
activity. ET also leads to damage in cardiac tissues. Histologically,
ET-treated mice have cardiac lesions, myocyte degeneration, and
increased separation of myoﬁbers. This eventually leads to areas
of necrosis (Firoved et al., 2005).
Given the damage that LT and ET directly cause on the heart,
there is little wonder that they also cause decreased cardiac out-
put. Puriﬁed LT injection has been shown to cause hypotension,
bradycardia, anddecrease the left ventricle ejection fraction (LVEF;
Moayeri et al., 2009; Sweeney et al., 2010). Moreover, delivering LT
induces an increase in the systolic and diastolic areas (Watson et al.,
2007a,b). Puriﬁed ET was noted to quickly induce hypotension
and tachycardia in both rats and canines. Intriguingly, injecting
recombinant ET does not increase hemoglobin or pleural ﬂuid
concentrations in the heart, suggesting that the decreased output
of the heart is not due to edema (Hicks et al., 2011). The puriﬁed
exotoxins are synergistic when administered together, leading to a
decrease in central venous pressure, an increase in heart rate, and
decreased LVEF. Similar results were also seen in the rat model
(Cui et al., 2007).
ENDOCRINE SYSTEM EFFECTS
Host inﬂammation and hormones are closely connected by regula-
tory circuits as a mechanism to quickly modulate the immune sys-
tem. Of particular interest has been the hypothalamus-pituitary-
adrenal (HPA) axis which releases glucocorticoids (GCs) into the
blood stream in response to bacterial and viral infections, general
toxic exposure, and pro-inﬂammatory cytokines (For review, see
Webster and Sternberg, 2004). GCs signal through glucocorticoid
receptors (GR) to inhibit NF-κB and AP-1 transcription, leading
to decreased immune activation. Puriﬁed LT is a non-competitive
inhibitor of GR activation in both in vitro and in vivo assays (Web-
ster et al., 2003; Moayeri et al., 2005). Only treatment with p38
MAPK inhibitors led to a similar reduction in GR activation, sug-
gesting the effect is due to LT’s inhibition of the p38 pathway.
Furthermore, similar repression could be seen with other nuclear
hormones depending on whether the assay focused on the simple
hormonepromoters or the complexmousemammary tumor virus
promoter. Interestingly, LT’s effect on GRs prevents gene activa-
tion, but does not affect gene repression (Webster and Sternberg,
2005).
Glucocorticoids are produced in the adrenal glands upon stim-
ulation by adrenocorticotrophin. The nascent glucocorticoids are
then able to act directly on the pituitary gland and hypothalamus
to down regulate their production of hormones via a negative
feedback loop (Webster and Sternberg, 2004). Mice that have
undergone adrenalectomies (ADX), and therefore are deﬁcient
in GCs, have greater sensitivity to puriﬁed LT-mediated death
than their control counterparts and have decreased GR-regulated
gene activation in vivo (Moayeri et al., 2005). This occurs in both
LT-sensitive BALB/cJ and LT-resistant DBA/2J mice. Since ADX
DBA/2J mice have greater sensitivity to LT, it implies this lethality
is due to a genetic locus distinct from Nalp1b. Macrophages from
ADX mice also have similar sensitivity/resistance proﬁles as con-
trol mice with intact GC signaling, further suggesting that Nalp1b
alleles are not involved with the increased sensitivity to LT injec-
tion elicited by endocrine alteration. In addition to reducing GC
production by ADX, GRs can be pharmacologically blocked by
a competitive inhibitor, RU486. BALB/cJ, but not DBA/2J, mice
that are pretreated with RU486 are more sensitive to death from
puriﬁed LT. It should be noted that BALB/cJ mice are hyper-GC
producers and produce pro-inﬂammatory cytokines in response
to LT due to pyroptosis. Therefore, it could be that BALB/cJ mice
are more sensitive to RU486 pretreatment because the inhibitor
prevents GC from dampening the pyroptotic response to LT, exac-
erbating the effect of pro-inﬂammatory cytokines. DBA/2J mice
are hypo-GC producers and therefore produce very low amounts
of GC in response to puriﬁed LT intoxication. Since RU486 is
a competitive inhibitor for GRs and DBA/2J mice produce low
amounts of corticosterone, only a slight effect would be seen with
this inhibitor (Moayeri et al., 2005).
Puriﬁed LT injection also induces four to ﬁve times greater lev-
els of an endogenous GC, corticosterone, in BALB/cJ mice but
not DBA/2J mice (Moayeri et al., 2005). This suggests that, at
least for these strains, higher GC levels correlate with LT-sensitive
strains. Additionally, treatment of either ADX or control DBA/2J
mice with dexamethasone (a synthetic GC) also exacerbates LT-
mediated death (Moayeri et al., 2005). This further suggests that LT
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does not inhibit GR-mediated gene activation at the ligand bind-
ing level. The authors speculate that dexamethasone may increase
susceptibility through altering the quantity or activity of GRs, or
HPA-independent mechanisms; such as working synergistically
with LT to inhibit p38 or other MEKs, modulating GC’s effects on
vasculature tone, or changing regulation of the hypoxic response.
Moreover, the fact that both ADX and exogenous GC supplemen-
tation lead to greater sensitivity to LT-mediated death may suggest
that disturbing the HPA axis by ADX or addition of GCs occur by
unique mechanisms.
Lastly, pretreatment with either puriﬁed LT or ET sensitizes
DBA/2J mice to puriﬁed LT-mediated death (Moayeri et al., 2005;
Firoved et al., 2007). It is not known if the sensitization caused
by pretreatment with LT is elicited by the same mechanisms that
occur after ADX. The authors speculated that there may be an
optimal number of GRs that need to be activated for protection
from LT injection. ET has been shown to increase corticosterone
serum levels in DBA/2J mice, which may lead to the increase in LT
sensitivity.
NEUROLOGICAL EFFECTS
Little work has focused on the effects of anthrax exotoxins on the
nervous system, despite the ability of B. anthracis to cause menin-
gitis and the role the sympathetic nervous system plays in vascular
homeostasis. Puriﬁed mixtures of LT and ET can rapidly cross
the BBB and cause changes in subcortical electroencephelograms
(EEGs) in as little as 30–60 s in Rhesus macaques and chim-
panzees (Vick et al., 1968). Additionally, the anthrax exotoxins
can induce coma or semi-consciousness between 5 and 10min
post-inoculation and elicit rapid changes to the nerve impulses in
the heart in about 1 h. Interestingly, the EEGs suggest that exo-
toxin is able to affect unique areas of the brain over time. Cortical
and subcortical EEGs show rapid changes occurring as soon as
5min after toxin injection. Cortical EEGs, which represent higher
brain functions, indicate a cessation of activity approximately 12 h
sooner than subcortical EEGs that measure lower brain functions.
Therefore, while the host may be comatose early after injection,
vital functions such as respiration and cardiac activity are still
maintained. The loss of activity with the subcortical EEG cor-
responds with decreasing phrenic nerve discharge, a respiratory
stimulus, and an ECG that suggests cardiac ischema (Vick et al.,
1968). Similar effects occur when Rhesus macaques are challenged
with B. anthracis Vollum spores (Klein et al., 1968). Since these
experiments, there have been few publications in this area until a
recent study that investigated the role of LT on the sympathetic
nervous system. The sympathetic nervous system has a role in
regulating blood pressure using specialized neurons called barore-
ceptors. Sprague-Dawley rats with either intact baroreceptors or
denervated baroreceptors were given an infusion of LT and both
had activation of the sympathetic nervous system, blood pres-
sure, and heart rate within minutes of exotoxin delivery. However,
denervated rats had higher levels of nerve activation, blood pres-
sure, and heart rate. The peak of sympathetic nerve discharge
occurred after the peak increase in blood pressure, suggesting that
nerve discharge is not the cause of the hypotension (Garcia et al.,
2012).
FIGURE 1 | General effects of edema toxin and lethal toxin on host
physiology. Lethal toxin can alter host responses in the immune,
cardiovascular, endocrine, and nervous system. At present, edema toxin has
known effects on the host cardiovascular, endocrine, and immune system.
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SUMMARY AND FUTURE DIRECTIONS
The exotoxins of B. anthracis were ﬁrst discovered by examining
their physiological effects in animal models. Before the exotoxin
proteins were identiﬁed, Smith et al. reported that ﬁltered plasma
from B. anthracis infected guinea pigs contained a “lethal factor”
and an“edema producing factor”(Smith andKeppie, 1954). Smith
and Keppie could not have known in the 1960s that the exotoxins
target critical andwell conserved pathways that are present inmost
cells, which lead to diverse effects throughout the host (Figure 1).
Recent and current studies are just now beginning to elucidate
which of these systems are ultimately important for the progres-
sion of and protection from B. anthracis. However, most of these
studies focus on the effect of LT on the host. Future work may be
able to determine what roles ET might have on similar systems.
Additionally, though several studies have measured amounts of
exotoxin in animal models, these studies have tended to detect rel-
atively high concentrations of exotoxin (10–100 ng/mL), typically
only looked in the serum, and in one case could only detect PA at
late stages of infection (Kobiler et al., 2006;Mabry et al., 2006; Tang
et al., 2009). More sensitive enzymatic assays could be employed to
investigate exotoxin concentrations at the earliest time points that
enable dissemination, establishment of infection, and the location
and concentration of exotoxin in particular organs. Perhaps this
data could also lead to a better understanding of primary and sec-
ondary effects of intoxication on an organ system. For example,
does increased vasculature permeability precede cardiac dysfunc-
tion? Lastly, it is important to keep inmind that toxemia is only one
part of anthrax and care should be taken to not over extrapolate
results derived from the use of puriﬁed exotoxins. For example,
LT may rapidly kill rats, but there are key differences between
the exotoxin-mediated death and the bacterial disease, such as,
vasculitis. Moreover, does the exotoxin prevent immune damage
to the vasculature from high levels of peptidoglycan when the
host is bacteremic? Hopefully, future studies will better deﬁne
the effects of the exotoxin and the bacteria on the physiology
of the host. Understanding how the exotoxins are able to sub-
vert these systems at a physiological level not only clariﬁes the
roles of exotoxins in infection, but better deﬁnes how the host
systems interact with each other in pathogenic and homeostatic
scenarios.
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